Infant Data
Results
INDICATIONS
Reversal of sedative effect from benzodiazepines, in cases of suspected benzodiazepines overdose, and in neonatal apnea secondary to prenatal benzodiazepine exposure.
ADVERSE EFFECTS
The reported experience in neonates is very limited. Use with caution in neonates with preexisting seizure disorders. Hypotension has been reported in adults following rapid administration. Resedation has been reported in 10% of treated pediatric patients, occurring 19 to 50 minutes after initial dosing. May cause pain on injection. Observe IV site for extravasation.
BLACK BOX WARNING
According to the manufacturer’s BLACK BOX WARNING, the use of flumazenil has been associated with the occurrence of seizures. Seizures are most frequent in patients who have been on benzodiazepines for long-term sedation.
ADMINISTRATION
- Intravenous: Administer 0.1 mg/mL (100 mcg/mL) as an IV bolus injection over 15 seconds through a free flowing intravenous infusion into a large vein.
- Rectal: Has been administered undiluted through a short, air-washed cannula in children.
MONITORING
Monitor for the return of sedation and respiratory depression. Continuous EKG and blood pressure.